These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21388580)

  • 21. Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease.
    Hirano M; Isono C; Sakamoto H; Ueno S; Kusunoki S; Nakamura Y
    Dysphagia; 2015 Aug; 30(4):452-6. PubMed ID: 25966655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 27. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 28. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
    Trenkwalder C; Kies B; Rudzinska M; Fine J; Nikl J; Honczarenko K; Dioszeghy P; Hill D; Anderson T; Myllyla V; Kassubek J; Steiger M; Zucconi M; Tolosa E; Poewe W; Surmann E; Whitesides J; Boroojerdi B; Chaudhuri KR;
    Mov Disord; 2011 Jan; 26(1):90-9. PubMed ID: 21322021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.
    Giladi N; Fichtner A; Poewe W; Boroojerdi B
    J Neural Transm (Vienna); 2010 Dec; 117(12):1395-9. PubMed ID: 21080009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
    BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
    Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
    Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
    Chung SJ; Kim JM; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    Expert Opin Pharmacother; 2015 May; 16(7):961-70. PubMed ID: 25846031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
    Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
    Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.
    Pierantozzi M; Placidi F; Liguori C; Albanese M; Imbriani P; Marciani MG; Mercuri NB; Stanzione P; Stefani A
    Sleep Med; 2016 May; 21():140-4. PubMed ID: 27448485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.